Vestmark Advisory Solutions Inc. lessened its holdings in Illumina, Inc. (NASDAQ:ILMN – Get Rating) by 12.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,332 shares of the life sciences company’s stock after selling 1,040 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Illumina were worth $1,483,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently modified their holdings of the business. Private Trust Co. NA acquired a new stake in Illumina in the 2nd quarter valued at $25,000. Zions Bancorporation N.A. increased its holdings in shares of Illumina by 97.6% in the 3rd quarter. Zions Bancorporation N.A. now owns 164 shares of the life sciences company’s stock worth $31,000 after acquiring an additional 81 shares during the period. Guardian Wealth Advisors LLC acquired a new stake in shares of Illumina in the 3rd quarter worth about $33,000. Massmutual Trust Co. FSB ADV increased its holdings in shares of Illumina by 50.0% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 183 shares of the life sciences company’s stock worth $35,000 after acquiring an additional 61 shares during the period. Finally, SOA Wealth Advisors LLC. increased its stake in Illumina by 282.7% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 199 shares of the life sciences company’s stock valued at $37,000 after buying an additional 147 shares during the period. Hedge funds and other institutional investors own 87.97% of the company’s stock.
Insider Transactions at Illumina
In other news, SVP Aimee L. Hoyt sold 3,917 shares of Illumina stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $199.06, for a total transaction of $779,718.02. Following the completion of the sale, the senior vice president now owns 2,881 shares of the company’s stock, valued at $573,491.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Aimee L. Hoyt sold 3,917 shares of the firm’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $199.06, for a total value of $779,718.02. Following the transaction, the senior vice president now owns 2,881 shares in the company, valued at $573,491.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Alexander Aravanis sold 5,398 shares of the firm’s stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $201.74, for a total value of $1,088,992.52. Following the completion of the transaction, the senior vice president now owns 2,922 shares in the company, valued at approximately $589,484.28. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,186 shares of company stock valued at $2,255,837. 0.13% of the stock is currently owned by corporate insiders.
Illumina Price Performance
Illumina (NASDAQ:ILMN – Get Rating) last announced its quarterly earnings results on Tuesday, February 7th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.11). Illumina had a negative net margin of 96.12% and a positive return on equity of 3.79%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the business earned $0.75 EPS. The company’s revenue for the quarter was down 9.2% compared to the same quarter last year. On average, sell-side analysts expect that Illumina, Inc. will post 1.41 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $290.00 price objective on shares of Illumina in a research note on Wednesday, February 8th. SVB Leerink lifted their target price on shares of Illumina from $249.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, February 8th. UBS Group reduced their price objective on shares of Illumina from $255.00 to $240.00 and set a “neutral” rating for the company in a research note on Tuesday, February 14th. Royal Bank of Canada cut their target price on shares of Illumina from $303.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, March 15th. Finally, Argus cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Wednesday, January 25th. They noted that the move was a valuation call. Three analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Illumina currently has an average rating of “Hold” and a consensus target price of $249.40.
Illumina Profile
Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.
Read More
- Get a free copy of the StockNews.com research report on Illumina (ILMN)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze, Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
